Eli Lilly just wagered up to $2.75 billion on AI-designed medicines, yet not one AI-discovered drug has full FDA approval. Here's why 2026 is the year the field finally gets tested against clinical reality.
Insilico Medicine has pushed rentosertib, a drug whose target and molecule were both generated by AI, into a pivotal Phase III trial. It's the clearest test yet of whether AI drug discovery can produce medicines that work, not just headlines.
A new peer-reviewed study cut AI-redesigned toxin genes into fragments and fed them to four commercial DNA screening tools. Two caught fragments as short as 50 nucleotides. Here's what that means ten weeks before a US screening deadline — and why the authors are still worried.
